Avalon GloboCare Corp. — fact timeline

Avalon GloboCare Corp. shareholders approved Approval to give the Board authority to effect a reverse stock split of the Company's issued common stock at a ratio between 1-for-2 and 1-for-25, with the exact ratio to be selected by the Board, to be effected before June 9, 2027 (the 'Reverse Stock Split Proposal') at the 2026-06-09 meeting.

“the stockholders approved the Reverse Stock Split Proposal. The result of the votes to approve the Reverse Stock Split Proposal was as follows: For Against Abstain Broker Non-Votes 3,605,584 741,154 17,952 0”

Avalon GloboCare Corp. shareholders approved Approval, for the purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of Series A-1 Warrants, Series A-2 Warrants, Placement Agent Warrants and shares issuable upon exercise thereof in connection with the February 2026 private placement (the 'February 2026 Warrant Issuance Propos at the 2026-06-09 meeting.

“the stockholders approved the February 2026 Warrant Issuance Proposal. The result of the votes to approve the February 2026 Warrant Issuance Proposal was as follows: For Against Abstain Broker Non-Votes 925,882 570,691 4,417 2,863,700”

Avalon GloboCare Corp. shareholders approved Advisory approval of the 2025 compensation of our named executive officer (the 'Say-on-Pay Proposal') at the 2026-06-09 meeting.

“the stockholders approved the Say-on-Pay Proposal . The result of the votes to approve the Say-on-Pay Proposal was as follows: For Against Abstain Broker Non-Votes 1,414,027 32,635 54,328 2,863,700”

Avalon GloboCare Corp. shareholders approved Approval of the Avalon GloboCare Corp. 2026 Stock Incentive Plan (the '2026 Plan Proposal') at the 2026-06-09 meeting.

“the stockholders approved the 2026 Plan Proposal. The result of the votes to approve the 2026 Plan Proposal was as follows: For Against Abstain Broker Non-Votes 880,827 618,585 1,578 2,863,700”

Avalon GloboCare Corp. shareholders approved Ratification of the appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“appointment of M&K as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non-Votes 4,250,597 110,736 3,357 0”

Avalon GloboCare Corp. shareholders approved Election of four (4) members of the Board to serve for a one-year term to expire at the 2027 annual meeting at the 2026-06-09 meeting.

“All of the four (4) nominees for director were elected to serve until the next annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”

Sam Knipper was appointed as Chief Financial Officer at Avalon GloboCare Corp..

“On June 3, 2026, the board of directors of Avalon GloboCare Corp. (the “Company”) appointed Luisa Ingargiola as the Company’s Chief Strategy Officer, and Sam Knipper as the Company’s Chief Financial Officer, in each case, effective June 3, 2026 (the “Effective Date”).”

Luisa Ingargiola was appointed as Chief Strategy Officer at Avalon GloboCare Corp..

“On June 3, 2026, the board of directors of Avalon GloboCare Corp. (the “Company”) appointed Luisa Ingargiola as the Company’s Chief Strategy Officer, and Sam Knipper as the Company’s Chief Financial Officer, in each case, effective June 3, 2026 (the “Effective Date”).”

Avalon GloboCare Corp. incurred loan of $250,000 with FirstFire Global Opportunities Fund, LLC at 18.75% of the principal amount.

“On June 2, 2026 (the “FirstFire Issue Date”), the Company issued promissory note to FirstFire Global Opportunities Fund, LLC (“FirstFire”) in the principal amount of $250,000 (inclusive of a $50,000 original issuance discount) (the “FirstFire Note”) for gross proceeds of $200,000 on the same terms and conditions of the Dune Note described above.”

Avalon GloboCare Corp. incurred loan of $250,000 with Dune Equity Holdings LLC at 18.75% of the principal amount maturing December 1, 2026.

“On June 1, 2026 (the “Dune Issue Date”), Avalon Globocare Corp. (the “Company”) issued promissory note to Dune Equity Holdings LLC (“Dune”) in the principal amount of $250,000 (inclusive of a $50,000 original issuance discount) (the “Dune Note”) for gross proceeds of $200,000.”

Avalon GloboCare Corp. entered into Promissory Note to FirstFire Global Opportunities Fund, LLC with FirstFire Global Opportunities Fund, LLC valued at $250,000 principal amount, $200,000 gross proceeds (effective 2026-06-02).

“On June 2, 2026 (the “FirstFire Issue Date”), the Company issued promissory note to FirstFire Global Opportunities Fund, LLC (“FirstFire”) in the principal amount of $250,000 (inclusive of a $50,000 original issuance discount) (the “FirstFire Note”) for gross proceeds of $200,000 on the same terms and conditions of the Dune Note described above.”

Avalon GloboCare Corp. entered into Promissory Note to Dune Equity Holdings LLC with Dune Equity Holdings LLC valued at $250,000 principal amount, $200,000 gross proceeds (effective 2026-06-01).

“On June 1, 2026 (the “Dune Issue Date”), Avalon Globocare Corp. (the “Company”) issued promissory note to Dune Equity Holdings LLC (“Dune”) in the principal amount of $250,000 (inclusive of a $50,000 original issuance discount) (the “Dune Note”) for gross proceeds of $200,000.”

Avalon GloboCare Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 15, 2026, Avalon GloboCare Corp. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. B”

Avalon GloboCare Corp. issued 287,411 shares (Feb 19), 230,739 shares (Feb 24), 750,522 shares (Feb 26) of common stock to warrant holders for net-exercise basis, no proceeds received.

“On each of February 19, 2026, February 24, 2026 and February 26, 2026, the Company issued 287,411, 230,739 and 750,522 shares of its common stock, respectively upon exercise of existing warrants on a net-exercise basis. The February 24, 2026 issuance of warrant exercise shares triggered the disclosure requirement under this Item 3.02. No proceeds were received upon exercise.”

Avalon GloboCare Corp. issued Placement Agent Warrants to purchase up to 318,628 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC (Placement Agent) for cash fee of 7.0% of aggregate gross proceeds plus management fee.

“H.C. Wainwright & Co., LLC as the exclusive placement agent in connection with the Private Placement (the “ Placement Agent ”), the Company paid the Placement Agent a cash fee of 7.0% of the aggregate gross proceeds raised in the Private Placement, plus a management fee equal to 1.0% of the gross proceeds raised in the Private Placement and reimbursement of”

Avalon GloboCare Corp. issued Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock of warrant to institutional investors for Each Warrant has an exercise price of $0.51 per share.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Avalon GloboCare Corp. issued Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock of warrant to institutional investors for Each Warrant has an exercise price of $0.51 per share.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Avalon GloboCare Corp. issued pre-funded warrants to purchase up to 5,882,353 shares of Common Stock of warrant to institutional investors for $0.5099 per Pre-Funded Warrant.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Avalon GloboCare Corp. issued 490,197 shares of common stock to institutional investors for $0.51 per Share.

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 490,197 shares (the "Shares") of the Company's common stock, par value $0.0001 per shares (" Common Stock ") at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the "Pre-Funded Warrants") at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common Stock (the " Pre-Funded Warrant Shares "); (iii) Series A-1 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-1 Warrants ," and the shares issuable upon exercise thereof, the " Series A-1 Warrant Shares ") and (iv) Series A-2 warrants to purchase up to 6,372,550 shares of Common Stock (the " Series A-2 Warrants ," together with the Series A-1 Warrants, the " Warrants ") and t”

Avalon GloboCare Corp. entered into Registration Rights Agreement with certain institutional investors (effective 2026-02-26).

“the Company entered into a registration rights agreement (the " Registration Rights Agreement "), dated as of February 26, 2026, with the Purchaser”

Avalon GloboCare Corp. entered into Purchase Agreements with certain institutional investors (effective 2026-02-26).

“On February 26, 2026, Avalon GloboCare Corp. (the " Company ") entered into securities purchase agreements (the " Purchase Agreements ") with certain institutional investors ("the " Purchasers ") for the issuance and sale in a private placement”

Avalon GloboCare Corp. issued 231,850 shares of common stock of common stock to Existing warrant holders for Net-exercise basis, no proceeds received.

“On each of February 19, 2026, February 24, 2026 and February 26, 2026, the Company issued 287,411, 230,739 and 231,850 shares of its common stock, respectively upon exercise of existing warrants on a net-exercise basis.”

Avalon GloboCare Corp. issued 230,739 shares of common stock of common stock to Existing warrant holders for Net-exercise basis, no proceeds received.

“On each of February 19, 2026, February 24, 2026 and February 26, 2026, the Company issued 287,411, 230,739 and 231,850 shares of its common stock, respectively upon exercise of existing warrants on a net-exercise basis.”

Avalon GloboCare Corp. issued 287,411 shares of common stock of common stock to Existing warrant holders for Net-exercise basis, no proceeds received.

“On each of February 19, 2026, February 24, 2026 and February 26, 2026, the Company issued 287,411, 230,739 and 231,850 shares of its common stock, respectively upon exercise of existing warrants on a net-exercise basis.”

Avalon GloboCare Corp. issued 6,372,550 Series A-2 warrants to purchase common stock of warrant to Certain institutional investors for Each warrant has an exercise price of $0.51 per share; issued as part of private placement.

“placement (the “ Private Placement ”) of (i) 490,197 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per shares (“ Common Stock ”) at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the “Pre-Funded Warrants”) at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common”

Avalon GloboCare Corp. issued 6,372,550 Series A-1 warrants to purchase common stock of warrant to Certain institutional investors for Each warrant has an exercise price of $0.51 per share; issued as part of private placement.

“placement (the “ Private Placement ”) of (i) 490,197 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per shares (“ Common Stock ”) at a purchase price of $0.51 per Share; (ii) pre-funded warrants (the “Pre-Funded Warrants”) at a purchase price of 0.5099 per Pre-Funded Warrant to purchase up to an aggregate of 5,882,353 shares of Common”

Avalon GloboCare Corp. entered into Purchase Agreements with certain institutional investors (effective 2026-02-26).

“On February 26, 2026, Avalon GloboCare Corp. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors”

Avalon GloboCare Corp. issued convertible note to an accredited investor for gross proceeds of $207,000.

“On February 19, 2026 (the “Issuance Date”), Avalon Globocare Corp. (the “Company”) entered into a securities purchase agreement (the “SPA”) with an accredited investor pursuant to which the Company issued to the investor a promissory note in the principal amount of $233,910 (inclusive of a $26,910 original issuance discount) (the “Note”) for gross proceeds of $207,000.”

Avalon GloboCare Corp. entered into SPA with an accredited investor valued at $233,910 (inclusive of a $26,910 original issuance discount) (effective 2026-02-19).

“On February 19, 2026 (the “Issuance Date”), Avalon Globocare Corp. (the “Company”) entered into a securities purchase agreement (the “SPA”) with an accredited investor pursuant to which the Company issued to the investor a promissory note in the principal amount of $233,910 (inclusive of a $26,910 original issuance discount) (the “Note”) for gross proceeds of $207,000.”

Avalon GloboCare Corp. amended Amendment #2 (effective 2026-02-15).

“On February 15, 2026, the Company entered into Amendment #2 (the “Note Amendment”) to unsecured bridge note dated December 11, 2025 in the original principal amount of $375,000 (the “Note”).”

Avalon GloboCare Corp. amended Amended and Restated Membership Interest Purchase Agreement with Wenzhao Lu valued at amended aggregated purchase price of $9,000,000 (effective 2026-02-18).

“On February 18, 2026, the Company and the Purchaser entered into an Amended and Restated Membership Interest Purchase Agreement (the “Amended MIPA”), pursuant to which the Company sold to the Purchaser 100% of the membership interests of Avalon RT9 for (i) the Cash Consideration and (ii) the satisfaction, in full, of an approximately $5,900,000 balance due on an existing mortgage financing.”

Avalon GloboCare Corp. completed a disposition involving Wenzhao Lu for $9,000,000 (closed 2026-02-18).

“and (ii) the satisfaction, in full, of an approximately $5,900,000 balance due on an existing mortgage financing. This represents a total amended aggregated purchase price of $9,000,000. As a result of the closing of this transaction, the Company has been relieved of all obligations as a guarantor on the mortgage that was associated with the property owned by”

Avalon GloboCare Corp. incurred debt of $233,910 with Vanquish Funding Group, Inc. at 12% maturing February 15, 2027.

“Funding Group, Inc. (the “Lender”), a Virginia corporation, under which it issued a promissory note dated February 11, 2026 on February 12, 2026 in the principal amount of $233,910, for a purchase price of $207,000, reflecting an original issue discount of $26,910 (the “Note”). The Note carries a one-time interest charge of 12% and is repayable in”

Avalon GloboCare Corp. entered into Purchase Agreement with Vanquish Funding Group, Inc. valued at $233,910 (effective 2026-02-12).

“On February 12, 2026, Avalon GoboCare Corp. (the “Company”) entered into a Securities Purchase Agreements dated February 11, 2026 (the “Purchase Agreement”) with Vanquish Funding Group, Inc. (the “Lender”), a Virginia corporation, under which it issued a promissory note dated February 11, 2026 on February 12, 2026 in the principal amount of $233,910, for a purchase price of $207,000, reflecting an original issue discount of $26,910 (the “Note”).”

Avalon GloboCare Corp. terminated Merger Agreement with YOOV Group Holding Limited (effective 2026-01-21).

“The Termination Agreement terminates in its entirety, effective as of January 21, 2026, the Agreement and Plan of Merger dated March 7, 2025, by and among Avalon, Merger Sub and YOOV (the “Merger Agreement”).”

Avalon GloboCare Corp. entered into Purchase Agreement with Allen O Cage Jr. valued at $375,000 (effective 2025-12-11).

“On December 11, 2025, Avalon GloboCare Corp., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Allen O Cage Jr., an individual (the “Holder”), pursuant to which the Company issued an unsecured bridge note (the “Note”) with a maturity date of April 15, 2026 (the “Maturity Date”), in the principal sum of $375,000 (the “Principal Sum”).”

Avalon GloboCare Corp.: Amended articles of incorporation to designate Series E Non-Voting Convertible Preferred Stock (effective 2025-12-12).

“On December 12, 2025, the Company filed a certificate of designations of preferences, rights, and limitations of Series E Non-Voting Convertible Preferred Stock (the “Series E Certificate of Designations”) with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of 19,500 shares of Series E Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions as set forth in the Series E Certificate of Designations.”

Avalon GloboCare Corp. incurred loan of $375,000 with Allen O Cage Jr. maturing April 15, 2026.

“On December 11, 2025, Avalon GloboCare Corp., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Allen O Cage Jr., an individual (the “Holder”), pursuant to which the Company issued an unsecured bridge note (the “Note”) with a maturity date of April 15, 2026 (the “Maturity Date”), in the principal sum of $375,000 (the “Principal Sum”).”

Avalon GloboCare Corp. completed an acquisition involving RPM INTERACTIVE, INC. for $19,500,000 (closed 2025-12-12).

“Delaware corporation (the “Company” or “Avalon”), acquired RPM INTERACTIVE, INC., a Nevada corporation (“RPM”), in accordance with the terms of the Agreement and Plan of Merger, dated December 12, 2025, as amended by Amendment No.”

Avalon GloboCare Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 19, 2025, the Company received a letter (the “November Nasdaq Letter”) from Nasdaq indicating that the Company was not in compliance with Listing Rule 5550(b). Unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), trading of the Company’s common stock would be subject to suspension/delisting. Accordingly, the Company plans to timely request a hearing before the Panel, which request will automatically stay any suspension or delisting action by Nasdaq pending the hearing and the expiration of any additional extension period granted by the Panel fol”

Avalon GloboCare Corp.: Amended beneficial ownership limitation in Series C Preferred Stock certificate of designations from 19.99% to 4.99% (effective 2025-05-29).

“On May 29, 2025, the Company filed a certificate of amendment to the Series C Certificate of Designations (the "Certificate of Amendment"), pursuant to which the beneficial ownership limitation of 19.99% was amended to 4.99%.”

Avalon GloboCare Corp. incurred convertible notes of $100,000 with two accredited investors at one-time interest charge of $30,000 maturing nine months from the date of issuance.

“On July 3, 2025, Avalon GloboCare Corp., a Delaware corporation (the “Company”) issued two Convertible Promissory Notes (each, a “Note” and collectively, the “Notes”) to two accredited investors (each, an “Investor” and together, the “Investors”), on identical terms. Each Note had a principal amount of $100,000, bears a one-time interest charge of $30,000, and matures nine months from the date of issuance.”

Avalon GloboCare Corp.: Amended beneficial ownership limitation in Series C Certificate of Designations from 19.99% to 4.99% (effective 2025-05-29).

“On May 29, 2025, the Company filed a certificate of amendment to the Series C Certificate of Designations (the “Certificate of Amendment”), pursuant to which the beneficial ownership limitation of 19.99% was amended to 4.99%.”

Avalon GloboCare Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 22, 2025, Avalon GloboCare Corp. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of ($3,891,270), as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, was below the required minimum of $2.5 million, and because, as of May 22, 2025, the Compa”

Avalon GloboCare Corp.: Reduced stockholder meeting quorum requirement to one-third of voting power (effective 2025-03-07).

“The Amendment reduces the quorum at any meeting of stockholders, except as otherwise required by law or by the Avalon Charter or the Avalon Bylaws, to one-third of the voting power of the shares of capital stock outstanding and entitled to vote at the meeting, present in person, present by remote communication, if applicable, or represented by proxy.”

Avalon GloboCare Corp.: Filed Certificates of Elimination to remove designations for Series A and Series B Preferred Stock from the certificate of incorporation (effective 2025-03-07).

“On March 7, 2025, Avalon filed a Certificate of Elimination relating to each of the Series A Preferred Stock and the Series B Preferred Stock (the “Eliminations of Designation”) with the Secretary of State of the State of Delaware, thereby terminating the designations of the Series A Preferred Stock and the Series B Preferred Stock.”

Avalon GloboCare Corp.: Filed Series C Certificate of Designations to designate 10,000 shares of Series C Convertible Preferred Stock with stated value, dividend, liquidation preference, and conversion terms (effective 2024-12-13).

“On December 13, 2024, the Company filed a certificate of designations of preferences, rights, and limitations of Series C Convertible Preferred Stock (the "Series C Certificate of Designations") with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of 10,000 shares of Series C Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions as set forth in the Series C Certificate of Designations.”

Avalon GloboCare Corp.: Reverse stock split at a ratio of 1-for-15 and decrease in authorized shares from 490,000,000 to 100,000,000 (effective 2024-10-25).

“On October 23, 2024, the Company filed a certificate of amendment (the “Amendment”) to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effectuate the Reverse Stock Split at a ratio of 1-for-15 as well as the Decreased in Authorized Shares. The Amendment became effective at 5:00 PM ET on October 25, 2024.”

Avalon GloboCare Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 2, 2024, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to October 28, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its Common Stock, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will provide notice”

Avalon GloboCare Corp. incurred convertible notes of $700,000.00 with Mast Hill Fund L.P. at 13%.

“the issuance of 13% senior secured promissory notes totaling $700,000.00 convertible into common stock”